PatientSpotlight, by PanaceaIntelPatientSpotlight

Topic · Respiratory

Access

Coverage of who can actually get diagnosis and treatment - payer dynamics, geographic variation, infrastructure constraints, and the international divergence that defines real-world access. 3 pieces on access in Respiratory, newest first within each collection.

← All topics
FilterAll (58)Oncology (2)Rare Disease (8)Immunology (2)Neurology (25)Cardiometabolic (4)Respiratory (3)Women's Health (5)Mental Health (7)Ophthalmology (2)

Signals

3
SignalApr 30, 2026

PAH combination therapy moves to first-line

Pulmonary arterial hypertension upfront combination therapy is becoming standard rather than sequential single-agent escalation.

TreatmentPatient journeyAccess
SignalApr 26, 2026registry

COPD triple-therapy uptake remains uneven across markets

Single-inhaler triple therapy in COPD is the guideline-supported regimen for the eligible population, but real-world uptake remains uneven across major markets driven by step-therapy protocols, prescriber inertia, and access geography.

TreatmentAccess
SignalApr 26, 2026FDA · peer-reviewed · conference

Severe asthma biologics: which patients are still being left out?

Type-2 biologics have transformed severe eosinophilic asthma management, but a meaningful subset of severe-asthma patients - those without high eosinophils, FeNO, or specific allergic phenotypes - still lack a biomarker-aligned biologic option.

TreatmentBiologicsPipelineAccess